Phenoxypropazine
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(1-methyl-2-phenoxy-ethyl)hydrazine
|
|
| Clinical data | |
| Routes of administration |
Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 3818-37-9 |
| ATC code | none |
| PubChem | CID 71467 |
| ChemSpider | 64548 |
| UNII | 8E92V52324 |
| ChEMBL | CHEMBL1909286 |
| Chemical data | |
| Formula | C9H14N2O |
| Molar mass | 166.22 g/mol |
Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family. It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.[1][2][3][4][5]
See also[edit]
References[edit]
- ^ LEAHY MR, ROSE JT, PLOWMAN R (April 1963). "A preliminary study of phenoxypropazine in the treatment of depression". The American Journal of Psychiatry. 119: 986–7. PMID 13928824.
- ^ IMLAH NW (May 1963). "Preliminary report on phenoxypropazine". The American Journal of Psychiatry. 119: 1091–2. PMID 13956423.
- ^ ROSE JT, LEAHY MR, PLOWMAN R (October 1963). "A comparison of phenoxypropazine and amitriptyline in depression". The American Journal of Psychiatry. 120: 393–5. PMID 14069469.
- ^ ROSE JT (March 1964). "Phenoxypropazine and chlordiazepoxide in depression". The American Journal of Psychiatry. 120: 899–900. PMID 14129290.
- ^ MCWHINNEY IR, MORRELL DC (January 1965). "Treatment of mild endogenous depression with a monoamine oxidase inhibitor: a controlled trial in general practice". The Journal of the College of General Practitioners. 9: 95–9. PMC 1878242
. PMID 14254271.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
